Cumberland Pharmaceuticals to Present at the UBS Global Life Sciences Conference in New York
NASHVILLE, Tenn., Sept. 6, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced that it will present a corporate overview at the UBS Global Life Sciences Conference at the Grand Hyatt New York on Wednesday, September 19, 2012, at 10:00 a.m. Eastern Time.
The presentation will be simultaneously webcast and can be accessed through the Investor Relations section of Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.
Shortly following the live webcast a replay will also be available on the Company's website.
About Cumberland Pharmaceuticals
Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® for the treatment of acetaminophen poisoning, Caldolor®, the first injectable treatment for pain and fever approved in the United States, and Kristalose®, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Company website at www.cumberlandpharma.com.
SOURCE Cumberland Pharmaceuticals Inc.